204 related articles for article (PubMed ID: 15245613)
1. Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer.
Carney WP; Neumann R; Lipton A; Leitzel K; Ali S; Price CP
Clin Breast Cancer; 2004 Jun; 5(2):105-16. PubMed ID: 15245613
[TBL] [Abstract][Full Text] [Related]
2. Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer.
Carney WP; Neumann R; Lipton A; Leitzel K; Ali S; Price CP
Clin Chem; 2003 Oct; 49(10):1579-98. PubMed ID: 14500583
[TBL] [Abstract][Full Text] [Related]
3. Fatty acid synthase activity regulates HER2 extracellular domain shedding into the circulation of HER2-positive metastatic breast cancer patients.
Vazquez-Martin A; Fernandez-Real JM; Oliveras-Ferraros C; Navarrete JM; Martin-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2009 Dec; 35(6):1369-76. PubMed ID: 19885560
[TBL] [Abstract][Full Text] [Related]
4. Circulating Her-2/neu extracellular domain in breast cancer patients-correlation with prognosis and clinicopathological parameters including steroid receptor, Her-2/neu receptor coexpression.
Barić M; Kulić A; Sirotković-Skerlev M; Dedić Plavetić N; Vidović M; Horvatić-Herceg G; Vrbanec D
Pathol Oncol Res; 2015 Jul; 21(3):589-95. PubMed ID: 25367073
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of HER2/neu oncoprotein in serum & tissue samples of women with breast cancer.
Shukla S; Singh BK; Pathania OP; Jain M
Indian J Med Res; 2016 May; 143(Supplement):S52-S58. PubMed ID: 27748278
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study.
Finn RS; Gagnon R; Di Leo A; Press MF; Arbushites M; Koehler M
J Clin Oncol; 2009 Nov; 27(33):5552-8. PubMed ID: 19858400
[TBL] [Abstract][Full Text] [Related]
7. Relationships between serum HER2 ECD, TIMP-1 and clinical outcomes in Taiwanese breast cancer.
Tsai HP; Chen SC; Chien HT; Jan YY; Chao TC; Chen MF; Hsieh LL
World J Surg Oncol; 2012 Feb; 10():42. PubMed ID: 22339939
[TBL] [Abstract][Full Text] [Related]
8. A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression.
Reix N; Malina C; Chenard MP; Bellocq JP; Delpous S; Molière S; Sevrin A; Neuberger K; Tomasetto C; Mathelin C
Breast Cancer Res Treat; 2016 Nov; 160(2):249-259. PubMed ID: 27709352
[TBL] [Abstract][Full Text] [Related]
9. Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662.
Hayes DF; Yamauchi H; Broadwater G; Cirrincione CT; Rodrigue SP; Berry DA; Younger J; Panasci LL; Millard F; Duggan DB; Norton L; Henderson IC;
Clin Cancer Res; 2001 Sep; 7(9):2703-11. PubMed ID: 11555582
[TBL] [Abstract][Full Text] [Related]
10. Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer.
Lee SB; Lee JW; Yu JH; Ko BS; Kim HJ; Son BH; Gong G; Lee HJ; Kim SB; Jung KH; Ahn JH; Lee W; Sung J; Ahn SH
BMC Cancer; 2014 Dec; 14():929. PubMed ID: 25491647
[TBL] [Abstract][Full Text] [Related]
11. Serum levels of HER2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma.
Sandri MT; Johansson H; Colleoni M; Zorzino L; Passerini R; Orlando L; Viale G
Anticancer Res; 2004; 24(2C):1261-6. PubMed ID: 15154657
[TBL] [Abstract][Full Text] [Related]
12. Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer.
Bramwell VH; Doig GS; Tuck AB; Wilson SM; Tonkin KS; Tomiak A; Perera F; Vandenberg TA; Chambers AF
Breast Cancer Res Treat; 2009 Apr; 114(3):503-11. PubMed ID: 18437556
[TBL] [Abstract][Full Text] [Related]
13. Serum HER2 in combination with CA 15-3 as a parameter for prognosis in patients with early breast cancer.
Di Gioia D; Dresse M; Mayr D; Nagel D; Heinemann V; Stieber P
Clin Chim Acta; 2015 Feb; 440():16-22. PubMed ID: 25444743
[TBL] [Abstract][Full Text] [Related]
14. High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor-positive metastatic breast cancer: a confirmatory prospective study.
Colomer R; Llombart-Cussac A; Lloveras B; Ramos M; Mayordomo JI; Fernández R; Tusquets I; Gil M; Barnadas A; Constenla M; Gilabert M; Alba E
Cancer; 2007 Nov; 110(10):2178-85. PubMed ID: 17926331
[TBL] [Abstract][Full Text] [Related]
15. Study of HER2/neu status in Qatari women with breast carcinoma.
Rasul KI; Mohammaed K; Abdalla AS; Chong-Lopez A; Ahmad MA; Al-Homsi MU; Al-Hassan AM; Al-Alosi AS; Bener A
Saudi Med J; 2003 Aug; 24(8):832-6. PubMed ID: 12939666
[TBL] [Abstract][Full Text] [Related]
16. The extracellular domain of Her2 in serum as a biomarker of breast cancer.
Perrier A; Gligorov J; Lefèvre G; Boissan M
Lab Invest; 2018 Jun; 98(6):696-707. PubMed ID: 29491426
[TBL] [Abstract][Full Text] [Related]
17. Serum HER2/ECD value in stage I and II early breast cancer: need of a lower cut-off?
Badzek S; Kelovic VL; Plestina S; Humar I; Veir Z; Mihaljevic Z
Wien Klin Wochenschr; 2011 Dec; 123(23-24):726-31. PubMed ID: 22113445
[TBL] [Abstract][Full Text] [Related]
18. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer.
Colomer R; Montero S; Lluch A; Ojeda B; Barnadas A; Casado A; Massutí B; Cortés-Funes H; Lloveras B
Clin Cancer Res; 2000 Jun; 6(6):2356-62. PubMed ID: 10873087
[TBL] [Abstract][Full Text] [Related]
19. Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer.
Müller V; Witzel I; Lück HJ; Köhler G; von Minckwitz G; Möbus V; Sattler D; Wilczak W; Löning T; Jänicke F; Pantel K; Thomssen C
Breast Cancer Res Treat; 2004 Jul; 86(1):9-18. PubMed ID: 15218357
[TBL] [Abstract][Full Text] [Related]
20. Serum HER2 extracellular domain levels and HER2 circulating tumor cell status in patients with metastatic breast cancer.
Aurilio G; Sandri MT; Pruneri G; Zorzino L; Botteri E; Munzone E; Adamoli L; Facchi G; Cullurà D; Verri E; Rocca MC; Zurrida S; Iacovelli R; Nolè F
Future Oncol; 2016 Sep; 12(17):2001-8. PubMed ID: 27255717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
